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Abstract
Background: Meningiomas are common brain tumors that are classified into three World Health
Organization grades (benign, atypical and malignant) and are molecularly ill-defined tumors. The
purpose of this study was identify molecular signatures unique to the different grades of
meningiomas and to unravel underlying molecular mechanisms driving meningioma tumorigenesis.
Results: We have used a combination of gene expression microarrays and array comparative
genomic hybridization (aCGH) to show that meningiomas of all three grades fall into two main
molecular groups designated 'low-proliferative' and 'high-proliferative' meningiomas. While all
benign meningiomas fall into the low-proliferative group and all malignant meningiomas fall into the
high-proliferative group, atypical meningiomas distribute into either one of these groups. High-
proliferative atypical meningiomas had an elevated median MIB-1 labeling index and a greater
frequency of copy number aberrations (CNAs) compared to low-proliferative atypical
meningiomas. Additionally, losses on chromosome 6q, 9p, 13 and 14 were found exclusively in the
high-proliferative meningiomas. We have identified genes that distinguish benign low-proliferative
meningiomas from malignant high-proliferative meningiomas and have found that gain of cell-
proliferation markers and loss of components of the transforming growth factor-beta signaling
pathway were the major molecular mechanisms that distinguish these two groups.
Conclusion: Collectively, our data suggests that atypical meningiomas are not a molecularly
distinct group but are similar to either benign or malignant meningiomas. It is anticipated that
identified molecular and CNA markers will potentially be more accurate prognostic markers of
meningiomas.
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Background
Meningiomas account for ~30% of all primary central
nervous system tumors [1]. These tumors are classified
into three WHO Grades based on histopathological crite-
ria. Approximately 80% of these tumors are WHO Grade
1 (benign), while the remaining 20% are either WHO
Grade 2 (atypical) or Grade 3 (malignant) tumors [2,3].
Treatment options for meningioma patients are limited to
traditional forms of cancer therapy, i.e. surgical resection
and radiation therapy. Meningioma patients face
extremely variable clinical outcomes [4]. While benign
meningioma patients can often be cured by surgical resec-
tion alone, atypical and malignant meningioma patients
have worse clinical outcomes [4]. Some benign meningi-
omas recur despite complete resection and/or occur in
locations that are not amenable to complete resection [5].
While local 5-year recurrence rates are 5% for benign men-
ingiomas, they are about 40% for totally resected atypical
meningiomas. Malignant meningiomas are associated
with high local recurrence rates and patients have an over-
all median survival of less than 2 years [6]. The his-
topathological based grading system has proved useful in
predicting prognosis and in defining treatment regimens
for meningiomas [7]. However, there remains considera-
ble variability in clinical outcomes within each grade,
especially among atypical meningiomas. Existing criteria
do not adequately predict the rates of tumor growth or the
likelihood of tumor recurrence. Also, the histopathologi-
cal classification system provides no information on
underlying molecular alterations. In contrast, a molecular
based classification system has the likelihood of being a
better prognostic indicator and is useful for identifying
alterations in pathways and networks that drive tumor
progression and growth [8]. The information obtained
can potentially be translated into more effective and less
toxic targeted therapies [8].
Meningiomas are cytogenetically well characterized but
are molecularly less defined [3]. Mutation of the neurofi-
bromatosis 2 (NF2) gene on chromosome 22q12 is a fre-
quent and early event in meningioma tumorigenesis [9].
Atypical and malignant meningiomas have more complex
genetic alterations with losses of the G1-S phase cell cycle
checkpoint regulators, CDKN2A and CDKN2B, and
p14ARF on chromosome 9p contributing to more aggres-
sive meningioma phenotypes [10]. High-throughput
techniques have been used to analyze the global genome
and transcriptome profiles of meningiomas with interest-
ing insights into the biology of meningiomas [11-15].
However, these studies have either surveyed limited
number of genes [14,15], analyzed limited number of
samples [11], focused on differences arising due to men-
ingioma location [12] or only investigated chromosomal
aberrations [13].
The purpose of this study was to identify unique molecu-
lar signatures that characterize the different grades of
meningiomas and to identify underlying molecular mech-
anisms driving meningioma tumorigenesis. We have per-
formed a comprehensive analysis of the expression
pattern of over 47,000 transcripts in 23 primary meningi-
omas of the three histopathological grades using oligonu-
cleotide microarrays. Copy number aberrations (CNA) in
the same 23 tumors were defined using array comparative
genomic hybridization (aCGH). We find that meningi-
omas of all three grades fall into two main molecular
groups designated 'low-proliferative' and 'high-prolifera-
tive' meningiomas. Gain of cell proliferation markers and
loss of transforming growth factor beta (TGF-β) signaling
are the main molecular mechanisms that distinguish
benign low-proliferative tumors from malignant high-
proliferative tumors.
Results
Global gene expression patterns
Twenty-three meningioma samples of the three his-
topathological grades were profiled using gene expression
microarrays to identify molecular signatures unique to
each group and to unravel underlying molecular mecha-
nisms of meningioma progression. We performed pair-
wise comparisons between the three WHO grades of men-
ingiomas using SAM analysis. 28 genes were differentially
expressed between Grade 1 and 2 meningiomas and no
genes were differentially expressed between Grade 2 and
Grade 3 meningiomas using a criterion of q < 0.05 and
fold > 2. In contrast, 1,212 genes (q < 0.05; fold > 2) were
differentially expressed between Grade 1 and Grade 3
meningiomas. Since SAM analysis utilizes the median
expression of individual genes within each group to calcu-
late fold changes, this result suggests that Grade 2 menin-
giomas were the most heterogeneous group with
expression profiles of individual tumors matching both
Grade 1 and Grade 3 meningiomas.
To identify meningioma tumors with similar expression
patterns, we performed unsupervised clustering on the
microarray data. This analysis yielded two main branches
of a dendrogram (Figure 1A). The left branch was desig-
nated the 'low-proliferative' group because it contained all
eight benign meningiomas while the right branch was
designated the 'high-proliferative' group because it con-
tained all eight malignant meningiomas. The atypical
meningiomas distributed into either group, with four
cases consistently falling into the 'low-proliferative' group
and two cases consistently falling into the 'high-prolifera-
tive' group. One atypical case, SF4151, clustered with
either group depending on the filtering criteria used and
was considered unique (Figure 1A). Similar results were
obtained when a principal component analysis of the
expression data was performed (Figure 1B). Once again,Molecular Cancer 2007, 6:64 http://www.molecular-cancer.com/content/6/1/64
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all eight benign meningiomas and four atypical meningi-
omas clustered into one group while all eight malignant
meningiomas and two atypical meningiomas clustered
into a second group. The atypical meningioma, SF4151,
was an outlier, not truly fitting into either group. Collec-
tively, this data suggests that meningiomas of all three his-
topathological groups fell into two main molecular
subtypes.
Histopathological characteristics
Since the Grade 2 meningiomas in our dataset were
molecularly similar to either Grade 1 or Grade 3 meningi-
omas, we assessed their histopathological characteristics
in greater detail (Table 1). Meningiomas are classified as
Grade 2 meningiomas if they have increased mitotic activ-
ity and/or have the presence of three of the following five
criteria: increased cellularity, high nuclear to cytoplasmic
ratio, prominent nucleoli, cellular pattern loss and foci of
spontaneous necrosis [16,17]. The presence of brain inva-
sion is also used as a criterion for a Grade 2 classification
[16,17]. All Grade 2 meningiomas in our dataset fit these
histopathological criteria (Table 1). Also, there were no
specific histopathological criteria that could distinguish
the 'low proliferative' Grade 2 meningiomas from the
'high proliferative' Grade 2 meningiomas.
Increased MIB-1 labeling indices have been associated
with an increased risk of recurrence in meningiomas and
are sometimes used as an accessory to grading meningi-
omas [18]. We therefore assessed the MIB-1 labeling indi-
ces of the meningioma dataset (Table 1). As anticipated,
the median MIB-1 labeling indices increased with his-
topathological grade, with values of 1.4 for Grade 1, 7.0
for Grade 2 and 14.1 for Grade 3 meningiomas. While the
MIB-1 labeling indices of the high proliferative Grade 2
meningiomas (median = 8.1; Range = 7.5–8.0) were
higher than the low-proliferative Grade 2 meningiomas
(median = 5.1; Range = 3.7–7.0), larger sample numbers
are required to confirm this trend.
Clinical outcome
Clinical patient data of the 23 profiled meningiomas are
summarized in Table 2. Although the sample numbers are
small, we assessed whether the low-proliferative atypical
meningiomas had a better clinical outcome when com-
pared to the high-proliferative atypical meningiomas.
Clinical outcome was measured as the disease status at 2
years post-surgery. Once again, SF4151, the atypical men-
ingioma with a unique profile was not included in the
analysis. Interestingly, this patient was dead at 2 years
post-surgery. As anticipated, benign meningioma patients
had a better clinical outcome when compared to malig-
nant meningiomas. Only 1 in 8 benign meningiomas had
recurred, while 7 in 8 resected malignant meningiomas
had recurred and 5 of these patients were dead at two
Gene expression profiling of meningiomas Figure 1
Gene expression profiling of meningiomas. A) Unsupervised 
hierarchical clustering of expression data derived from 23 primary 
meningioma tumors of the three histopathological grades was per-
formed. Each column represents one case and each row repre-
sents the expression value of an individual probeset. Expression 
values are color coded as follows: higher (red), lower (green) or 
close (black) to the median expression value of each probeset. 
Tumor case numbers are listed above each column and are color-
coded by histopathological grade. Red, Grade 1; Green, Grade 2; 
and Blue, Grade 3. The classification tree on top suggests two 
major molecular subgroups of meningiomas. The asterisk refers to 
the Grade 2 meningioma with a unique expression pattern. B) 
Principal component analysis of the meningioma expression pro-
files. Distribution of the 23 primary meningioma tumors along the 
three calculated principal components, PC1, PC2 and PC3. Tumor 
cases are color coded by histopathological grade. Red, Grade 1; 
Green, Grade 2; and Blue, Grade 3.M
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Table 1: Histopathological Characteristics of Meningioma Tumors
SF4271 SF4287 SF4316 SF4465 SF4881 SF4886 SF4894 SF4931 SF3072 SF3118 SF3363 SF3411 SF4151 SF2176 SF3622 SF2841 SF3476 SF3595 SF3693 SF3938 SF4005 SF4290 SF4457
Grade BENIGN (GRADE 1) ATYPICAL (GRADE 2) MALIGNANT (GRADE 3)
Molecular 
Subgroup
LOW-PROLIFERATIVE * HIGH-PROLIFERATIVE
Embolized No Y Y No No No No Y No Y No Y No No No Y Y No N Y Y Y No
Histological 
Subtype
MTMMF iTTT C C
Mitotic 
Index
N N N N N E/F E/F N N N N N E/F N E/F E E/F E E E E E E
Increased 
Cellularity
E/F N N N N N E/F N N E/F E/F E E/F E E E E E E E E E E
Nuclear/
Cytoplasmic 
Ratio
E/F N E/F N N E/F E/F N E E E E N E/F E/F E F E E E E E E
Prominent 
Nucleoli
E/F N E/F N N E/F E/F N E E E E N E/F E/F E F E E E E E E
Cellular 
Pattern Loss
E/F N N N N N E/F N N E/F E/F E E/F E E E E/F E E E E E E
N e c r o s i sE / F E / F E / F NNNNNNNNENNE E E EE / FE E E E
Brain 
Invasion
Y YY
MIB-1 1.5 1.6 2.0 0.9 0.8 0.1 1.3 1.9 5.9 4.2 3.7 7.0 7.0 7.7 8.5 10.9 11.3 17.5 20.3 16.9 7.5 7.5 23.3
No = No; Y = Yes; M = Meningothelial; T = Transitional; Fi = Fibroblastic; CC = Clear Cell Characteristics N = Not Elevated or Absent; E = Elevated; F = Focal; §E indicates a mitotic index of >4 mitosis/10 high 
powered field while N indicates <4 mitosis/10 high powered field; * Refers to the Grade 2 meningioma that was an outlier
Table 2: Patient Clinical Data of the 23 Profiled Meningiomas
SF4271 SF4287 SF4316 SF4465 SF4881 SF4886 SF4894 SF4931 SF3072 SF3118 SF3363 SF3411 SF4151 SF2176 SF3622 SF2841 SF3476 SF3595 SF3693 SF3938 SF4005 SF4290 SF4457
Grade BENIGN (GRADE 1) ATYPICAL (GRADE 2) MALIGNANT (GRADE 3)
Molecular 
Subgroup
LOW-PROLIFERATIVE * HIGH-PROLIFERATIVE
Embolize
d
No Y Y No No No No Y No Y No Y No No No Y Y No N Y Y Y No
S e x FFFFFFFFFFFFFFMFFFFFMFF
Age 58 57 74 72 56 51 65 35 39 62 63 47 64 60 43 83 71 52 52 58 74 58 67
L o c a t i o nCCCSCCSSCCI sSCFTTCCCCCC
Primary or 
Recurrent
PPPPPPPPPPPPPPPPPRRPPPR
Extent of 
Resection
GGS uGGGGGGS uGGGGGS u S u S u S uGGGG
Disease 
Status@2yr
N RN R R N RN RN RN RN RN RN R U N R D N R R D R D D R D N R D
F = Female; M = Male; C = Convexity; S = Skull Base; I = Intraventricular; s = spinal; F = Falx; T = Tentorium; P = Primary; R = Recurrent; G = Gross Total Resection; Su = Sub Total Resection; NR = Non-Recurrent; R = Recurrent; D = Dead; U = Unknown;* Refers 
to the Grade 2 meningioma that was an outlierMolecular Cancer 2007, 6:64 http://www.molecular-cancer.com/content/6/1/64
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years. One patient belonging to the low-proliferative atyp-
ical meningiomas was lost to follow-up. Among the
remaining 5 atypical meningiomas, the only patient that
had recurrent disease was a high-proliferative atypical
meningioma. This is consistent with the high-proliferative
atypical meningiomas having a more aggressive clinical
course when compared to the low-proliferative atypical
meningiomas. However, larger sample numbers are
needed to confirm this trend.
aCGH changes
To correlate expression data with genome copy number
alterations, we performed aCGH on the identical set of 23
meningiomas used for the gene expression analysis. Chro-
mosomal alterations were observed in 7 of 8 (88%)
benign, 6 of 7 (86%) atypical and 8 of 8 (100%) malig-
nant meningiomas (Figure 2). Interestingly, while chro-
mosomal gains were observed, no gene amplifications (>4
copy numbers) were detected in this set of 23 meningi-
omas. Globally, chromosomal losses were far more fre-
quent than chromosomal gains. As anticipated, the
number of total chromosomal alterations in individual
tumors increased with the histopathological grade (Figure
2). The average number of chromosomal alteration was 1
for benign, 5 for atypical and 11.6 for malignant menin-
giomas. The most frequent deletion was loss of chromo-
some 22 (78.3%), followed by losses of regions of
chromosome 14q (60.9%) and chromosome 1p (56.5%).
Other chromosomal changes that were found in greater
than 20% of the tumors were losses on chromosome 3p,
6q, 10, 14q and 18 and gains on chromosome 1q.
We next analyzed if the two main molecular groups of
meningiomas had specific chromosomal alterations.
SF4151, the atypical meningioma that had a unique
expression profile, was not included in this analysis.
SF4151 had no detectable gross chromosomal aberra-
tions, an unusual characteristic for an atypical meningi-
oma (Figure 2). The two atypical meningiomas that were
similar to malignant meningiomas did have a greater
number of total chromosomal alterations when com-
pared to the atypical meningiomas that were similar to the
benign meningiomas. Several deletions/gains were found
exclusively in the high-proliferative meningioma sub-
group. Losses on chromosome 6q, 9p, 13 and 14 were all
found at a frequency of greater than 40% in the high-pro-
liferative subgroup.
Correlation between CNAs and gene expression
We evaluated correlations among CNAs by chromosomal
location, and also between CNAs and expression levels of
genes mapping to the same locus. In addition to the antic-
ipated correlation between CNAs in neighboring regions
on the same chromosomes (Figure 3A; diagonal line), sev-
eral additional correlations between CNAs on different
chromosomes were observed (Figure 3A). While CNAs
and gene expression levels at the same locus were posi-
tively correlated, this relationship varied along the
genome (Figure 3B; diagonal line). Once again, positive
and negative DNA-RNA correlations away from the diag-
onal of the matrix plot were observed. Positive correlation
between chromosome 14 and 6q, and the inverse correla-
tions between chromosome 14 and 1q and chromosomes
20 and 7q were maintained among CNAs and between
CNAs and gene expression (Figure 3). This suggests that
Copy number aberrations of meningiomas Figure 2
Copy number aberrations of meningiomas. Array-
comparative genomic hybridization data derived from 23 pri-
mary meningioma tumors were processed to identify loss 
(grey boxes), gain (black boxes) or both loss and gain (pat-
terned boxes) of part or all of a given chromosomal arm. 
Each column represents one case and each row represents 
the indicated chromosomal arm. The WHO Grades and the 
molecular subgroups of the individual cases are indicated 
below the case numbers. The asterisk refers to the Grade 2 
meningioma with a unique expression pattern.Molecular Cancer 2007, 6:64 http://www.molecular-cancer.com/content/6/1/64
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the mechanism of gene expression changes was due to
DNA copy number alterations.
Molecular mechanisms underlying meningioma 
progression
A subset of the genes differentially expressed between
Grade 1 and 3 meningiomas (q < .05; fold > 4) are listed
[see Additional File 1 and Additional File 2]. This
included novel genes that have not been implicated in
meningioma pathogenesis and several genes that have
previously been reported as altered in meningiomas. It is
well established that loss of the progesterone receptor
(PR) is observed in Grade 3 meningiomas compared to
Grade 1 meningiomas [19,20]. In our dataset, transcript
levels of PR were reduced in Grade 3 meningiomas. In
addition, we found induction of IGFBP3, CENPF, CKS2
and reduction of LTBP2, PTPRF in high-grade meningi-
omas as previously reported [15].
To identify molecular mechanisms that underlie Grade 1
to Grade 3 meningioma progression, we analyzed differ-
entially expressed genes (p < 0.05 and fold > 2) using the
GenMAPP software package [21]. This program analyzes
gene expression in the context of known biological path-
ways and functions by mapping genes to Gene Ontology
and Contributed MAPPs and calculating a confidence
level based on the percentage of altered genes assigned to
each pathway [22,23]. Biological pathways, cellular com-
ponents and functions that were significantly altered
between Grade 1 and Grade 3 meningiomas included cell
cycle and mitosis related genes, extracellular matrix com-
ponents and the TGF-β signaling pathway (Table 3).
Table 3: Pathways significantly altered between grade 1 and 
grade 3 meningiomas by GenMAPP analysis of genes altereda
Database Mapp or GO name P value Number 
Changedb
Percent 
Changedc
Local 
Mapp
Hs 2 Tissues Endocrine 
and CNS
0.000 25 24.3
M phase of mitotic cell 
cycle
0.001 26 21.7
extracellular matrix 
(sensu Metazoa)
0.008 32 18.6
Hs TGF Beta Signaling 
Pathway
0.008 14 26.9
M phase 0.010 29 18.8
Hs Focal adhesion 
KEGG
0.012 33 17.6
Hs 1 Tissue Embryonic 
Stem Cell
0.044 12 25.5
Gene 
Ontology
spindle organization and 
biogenesis
0.000 11 57.9
extracellular matrix 0.000 50 19.6
extracellular matrix 
(sensu Metazoa)
0.001 49 19.7
cell division 0.017 33 22.1
extracellular region 0.023 117 12.1
spindle 0.024 11 39.3
cell adhesion 0.025 73 13.7
mitotic cell cycle 0.026 33 19.2
mitosis 0.049 26 21.1
aThe results were obtained using a criterion of p ≤ 0.05 and fold-
difference ≥ 2. bThe number of genes mapping to a particular pathway 
that are altered is listed. cThe percentage of total genes belonging to a 
particular pathway that are altered is listed.
Correlation matrices of genome copy number and gene  expression in meningiomas Figure 3
Correlation matrices of genome copy number and 
gene expression in meningiomas. A, Pearson's correla-
tions among DNA copy numbers (Panel A) and between 
DNA copy number and gene expression (Panel B) are plot-
ted as a function of chromosomal location. Only correlations 
greater than 0.82 (red) and less than -0.82 (blue) are shown 
on the intensity map. The association between loss on chro-
mosome 14 and gain on chromosome 1q (black arrow), loss 
on chromosome 14 and loss on chromosome 6q (brown 
arrow) and loss on chromosome 7p and gain on chromo-
some 20 (black arrowhead) are indicated.Molecular Cancer 2007, 6:64 http://www.molecular-cancer.com/content/6/1/64
Page 7 of 10
(page number not for citation purposes)
TGF-β pathway alterations in meningiomas
Fourteen genes that participate in TGF-β signaling were
differentially expressed between Grade 1 and Grade 3
meningiomas (Table 4). The majority of these compo-
nents had reduced expression levels in Grade 3 meningi-
omas, suggesting loss of TGF-β signaling as a mechanism
contributing to the development of higher-grade menin-
giomas. In the case of five genes, we confirmed differences
at the transcript levels using quantitative PCR in 10 Grade
1 (5 cases represented in the microarray and 5 independ-
ent cases) and 10 Grade 3 (5 cases represented in the
microarray and 5 independent cases) meningiomas (Fig-
ure 4). In line with the microarray data, the PCR data
showed a decrease in the median expression level of
BMP4, SMAD9, JUN, RUNX2 and an increase in the
median expression level of FKBP1A in Grade 3 meningi-
omas when compared to Grade 1 meningiomas.
Discussion
We have profiled gene expression changes and genomic
CNAs of primary meningioma tumors belonging to the
three WHO malignancy grades. Independent methods of
analysis of the expression data revealed that meningiomas
of all three grades can be classified into two main molec-
ular groups. We have designated these molecular groups
as the low-proliferative and the high-proliferative menin-
giomas to reflect the fact that all the slower-growing
benign tumors fell into the former group and all the
faster-growing malignant tumors fell into the latter group.
Atypical meningiomas did not have a unique molecular
signature of their own. Instead, their molecular profiles
matched those of either benign or malignant meningi-
omas. Clinically, atypical meningiomas demonstrate a
wide variability in clinical behaviour, with some tumors
exhibiting growth patterns similar to benign meningi-
omas and others having poor clinical outcomes parallel-
ing those of malignant meningiomas [4]. Our data
suggests that molecular signatures could distinguish the
slower-growing atypical meningiomas from the more
aggressive ones.
Previous attempts at profiling the expression pattern of
meningiomas were unable to reliably distinguish the dif-
ferent grades of meningiomas and identify specific expres-
sion patterns that were representative of each grade
[14,15]. In these prior studies, the two molecular classes
Transcript abundance of components of the transforming  growth factor-β signaling pathway in meningiomas Figure 4
Transcript abundance of components of the trans-
forming growth factor-β signaling pathway in menin-
giomas. Relative transcript numbers of BMP4, SMAD9, JUN, 
RUNX2 and FKBP1A in individual Grade 1 (B) and Grade 3 
(M) meningioma tumors (filled diamonds) are plotted. The 
data was derived either from microarray or from quantitative 
PCR analysis. The median expression level of the genes in 
each group is marked by a horizontal line.
Table 4: TGF-β Signaling Pathway Components Significantly 
Altered
Gene 
Symbol
Gene Name Probe Set IDa Fold 
Changeb
RUNX2 runt-related transcription factor 
2
232231_at -6.1
THBS1 thrombospondin 1 201108_s_at -5.3
JUN jun oncogene 201465_s_at -4.0
NOG noggin 231798_at -3.6
FST follistatin 226847_at -3.6
SMAD7 SMAD family member 7 204790_at -3.0
BMP4 bone morphogenetic protein 4 211518_s_at -2.6
SMAD9 SMAD family member 9 206320_s_at -2.5
SKI v-ski sarcoma viral oncogene 
homolog
204270_at -2.4
TGFBR3 transforming growth factor, 
beta receptor III
204731_at -2.3
FOS v-fos FBJ murine osteosarcoma 
viral oncogene homolog
201809_s_at -2.0
ENG endoglin 201809_s_at -2.0
FKBP1A FK506 binding protein 1A 210187_at 2.2
SPP1 secreted phosphoprotein 1 1568574_x_at 2.5
aThe corresponding affymetrix probe set ID that was altered is listed. 
bA negative fold change indicates a decrease in grade 3 meningiomas 
compared to grade 1 meningiomas and a positive number indicates an 
increase in grade 3 meningiomas compared to grade 1 meningiomas.Molecular Cancer 2007, 6:64 http://www.molecular-cancer.com/content/6/1/64
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of meningiomas were probably not clearly distinguisha-
ble because of the considerably fewer number of genes
surveyed. The considerable morphologic and biological
heterogeneity of meningiomas was thought to be respon-
sible for the lack of consistent molecular profiles, and
atypical and malignant meningiomas were grouped
together and compared to benign meningiomas [14,15].
Interestingly, one of these studies did report that a set of
genes could be used for a clear distinction between benign
and malignant meningiomas [15].
Using histopathological criteria, atypical meningiomas
were a distinct group and no specific criteria, except for
MIB-1 labeling indices, could distinguish the low-prolifer-
ative atypical meningiomas from the high-proliferative
atypical cases. Additional studies with larger numbers of
samples are needed to verify the molecular classification
scheme, confirm differences in the MIB-1 labeling indices
and perform clinical correlates.
Cytogenetically, the profile of our meningioma dataset is
similar to prior reports on meningiomas [13]. We have
identified several cytogenetic changes including losses on
chromosome 9p, 6q, 13 and 14 that were exclusively
found in the high-proliferative meningiomas. Losses of
chromosome 9p have previously been implicated in the
malignant progression of meningiomas and has been
associated with a poor prognosis in malignant meningi-
omas [24]. It is likely that one or more of these chromo-
somal regions contain tumor suppressors that are
responsible for progression of low-proliferative meningi-
omas to high-proliferative meningiomas. Losses of cyclin
dependent kinase inhibitors, CDKN2A and CDKN2B,
have been implicated as the tumor suppressor genes on
chromosome 9p responsible for malignant meningioma
phenotypes [10,25].
We have focused on alterations between benign and
malignant meningiomas since these histopathological
groups are the ones that can be reliably distinguished.
These altered genes are also potential candidates for mark-
ers that can classify atypical meningiomas into either the
low-proliferative or the high-proliferative groups. Among
these genes were several cell cycle related genes and com-
ponents of the TGF-β signaling pathway. The role of the
TGF-β signaling pathway in the pathogenesis and malig-
nant progression of meningiomas is unclear. Normal
meninges synthesizes and secretes all three isoforms of
TGF-β and these are present in the cerebrospinal fluid at
concentrations that activate TGF-β receptors [26,27]. TGF-
β1 inhibits proliferation of meningeal and benign menin-
gioma cells and this appears to be mediated by signaling
through the SMAD 2/3 pathway [28]. Thus, it seems likely
that TGF-β exerts an inhibitory effect on benign meningi-
omas and that loss of TGF-β signaling and/or resistance to
the growth inhibitory effects of TGF-β results in progres-
sion to malignancy. Our expression data supports this
hypothesis.
In summary, even though our sample numbers are lim-
ited, the combination of the large numbers of genes sur-
veyed and several different types of analysis allowed the
identification of two meningioma molecular classes. MIB-
1 labeling data, cytogenetic data and the clinical data are
all consistent with the classification into low-proliferative
and high-proliferative meningiomas.
Conclusion
We provide evidence for the existence of a two group
molecular classification scheme for meningiomas based
on molecular signatures. Our data suggests that molecular
and CNA markers will be able to distinguish low-prolifer-
ative atypical meningiomas from high-proliferative atypi-
cal meningiomas and will potentially be more accurate
predictors of atypical meningioma tumor growth than
histopathological criteria. It is envisaged that, in the
future, these markers will be used in conjunction with his-
topathological grading to determine the prognosis and
treatment regimens of atypical meningioma patients.
Methods
Tumor samples
All human meningioma tumor samples were collected by
the Neurological Surgery Tissue Bank using protocols
approved by the UCSF Committee on Human Research. A
neuropathologist (S.V.) graded each case using the revised
2000 WHO grading system [2]. A total of 23 (8 Grade I, 7
Grade II and 8 Grade III) meningiomas were used in the
current analysis. H&E stained sections adjacent to the fro-
zen meningioma tumor pieces were examined to confirm
tumor histologies.
RNA expression arrays
Total RNA was isolated from snap-frozen tumor samples
using the RNAeasy Kit (Qiagen, Valencia, CA) following
manufacturer's instructions and the quality of the RNA
was confirmed using the RNA 6000 Nano kit (Agilent
Technologies, Foster City, CA). Gene expression profiles
for individual tumors were generated by hybridization to
the Human Genome U133 Plus 2.0 oligonucleotide array
(Affymetrix, Santa Clara, CA) using previously described
protocols [29]. This array contains 54,000 probe sets and
over 47,000 transcripts, including 38,500 well-character-
ized genes.
Expression measures were generated from raw probe level
data (CEL  files) using the robust multi-array average
(RMA) function of the affy package [30,31]. The preproc-
essing involved background-adjustment, normalization
and log transformation. Presence-absence calls for expres-Molecular Cancer 2007, 6:64 http://www.molecular-cancer.com/content/6/1/64
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sion of probesets were made using the panp package [30].
Unsupervised hierarchical clustering was performed using
Ward's linkage method with Euclidean distances and the
hclust function in the R package. The data were filtered to
limit the probe sets to probesets that had a standard devi-
ation of greater than 0.5, which gave us 12,374 probe sets
out of the total 54,675 represented on the array. Principal
component analysis was performed using the princomp
function of the R stats package.
Differentially expressed genes between histopathological
grades were identified using the siggenes package [30].
Significance Analysis of Microarrays (SAM) two-class
unpaired analysis was used to calculate p-values, q-values
and fold changes in expression levels [32]. The calculated
gene expression changes were analyzed in the context of
known biological pathways and functions using Gen-
MAPP 2.1 [21,22]. Significant associations with GO bio-
logical process, molecular function, cellular component
groups and with contributed GenMAPP biological path-
ways were obtained with MAPPFinder 2.0 using the Hs-
Std_20060526 database [23].
aCGH
Genomic DNA was isolated from meningioma primary
tumors and from normal whole blood from anonymous
donors using the DNAeasy kit (Qiagen, Valencia, CA) fol-
lowing manufacturer's directions. The DNA was labeled
and hybridized to arrays spotted with 2,464 mapped bac-
terial artificial chromosomes (BAC) covering the whole
genome as described earlier [33]. The array images were
processed using the SPOT custom software [34]. Briefly,
relative ratios of tumor to normal DNA copy number for
individual BACs were normalized by setting the value of
the median relative ratio for that hybridization to 1. The
data was then log transformed. Losses or gains for that
tumor were scored as described earlier [35]. Copy number
frequency maps were constructed by applying circular
binary segmentation (CBS) algorithm to each aCGH pro-
file and aggregating the CBS smoothed profiles from all
the samples [36].
aCGH and expression correlations
Individual BACs were mapped to the University of Cali-
fornia, Santa Cruz genome database March 2006 freeze
[37]. Probesets were mapped to chromosomal locations
and the correlation between CNAs and gene expression
was determined by calculating Pearson's correlations as
previously described [38].
Quantitative PCR
Quantitative PCR was performed on cDNA templates with
the I-cycler machine (Bio-Rad, Hercules, CA) and SYBR
Green I (Molecular Probes, Eugene, OR) using PCR condi-
tions and data analysis as described earlier [11]. The prim-
ers used were as follows: BMP4  – 5'-
TGGCTGTCAAGAATCATGGA and 5'-CTTCCCCGTCT-
CAGGTATCA; FKBP1A – 5'-CCTTTGCTCCTCCCATGTTA
and 5'-CACATGCCAATTCCTTTCCT; SMAD9 – 5'-ACAG-
CAGCATCTTTGTGCAG and 5'-AAAGCCGTGGTGAACT-
GACT;  JUN  – 5'-GCAGCCCAAACTAACCTCAC and 5'-
CAGGGTCATGCTCTGTTTCA and RUNX2 – 5'-CAGAC-
CAGCAGCACTCCATA and 5'-CAGCGTCAACACCAT-
CATTC. Primers specific for the housekeeping gene, beta-
actin (5'-ACTCTTCCAGCCTTCCTTCC and 5'-CAGGAG-
GAGCAATGATCTTG), were used to verify the integrity of
the cDNA and to normalize cDNA yields.
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